Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
暂无分享,去创建一个
Eugen Trinka | Simona Lattanzi | Cinzia Del Giovane | Francesco Brigo | Mauro Silvestrini | M. Silvestrini | G. Zaccara | S. Lattanzi | Francesco Brigo | E. Trinka | Gaetano Zaccara | C. Cagnetti | Claudia Cagnetti | C. Del Giovane
[1] G. Krauss,et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome , 2008, Neurology.
[2] David Mawdsley,et al. Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics , 2018, Journal of clinical epidemiology.
[3] M. Silvestrini,et al. Efficacy and safety of perampanel in Parkinson’s disease. A systematic review with meta-analysis , 2018, Journal of Neurology.
[4] E. Thiele,et al. Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy , 2015, Epilepsia.
[5] M. Silvestrini,et al. Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis , 2018, CNS Drugs.
[6] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[7] J. Conry,et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome , 2011, Neurology.
[8] I. Scheffer,et al. Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome , 2017, The New England journal of medicine.
[9] M. Silvestrini,et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta‐analysis , 2018, Acta neurologica Scandinavica.
[10] Rongrui Tang,et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. , 2017, The New England journal of medicine.
[11] Y. M. Hart,et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy , 1995, The Lancet.
[12] M. Silvestrini,et al. Eslicarbazepine acetate as adjunctive treatment in partial‐onset epilepsy , 2018, Acta neurologica Scandinavica.
[13] Benjamin J. Whalley,et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.
[14] D. Thurman,et al. How common are the “common” neurologic disorders? , 2007, Neurology.
[15] Eric Marsh,et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial , 2018, The Lancet.
[16] M. Silvestrini,et al. Lacosamide monotherapy for partial onset seizures , 2015, Seizure.
[17] Anup D. Patel,et al. Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results , 2018, Epilepsia.
[18] M. Silvestrini,et al. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis , 2017, Journal of Neurology.
[19] O. Dulac,et al. Stiripentol in Childhood Partial Epilepsy: Randomized Placebo-Controlled Trial with Enrichment and Withdrawal Design , 2006, Journal of child neurology.
[20] M. Silvestrini,et al. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis , 2018, Cerebrovascular Diseases.
[21] M. Silvestrini,et al. Endovascular treatment of symptomatic vertebral artery stenosis: A systematic review and meta-analysis , 2018, Journal of the Neurological Sciences.
[22] M. Silvestrini,et al. Brivaracetam add-on for refractory focal epilepsy , 2016, Neurology.
[23] Michael Bazelot,et al. Molecular Targets of Cannabidiol in Neurological Disorders , 2015, Neurotherapeutics.
[24] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[25] B. Vickrey,et al. Cannabinoids for epilepsy. , 2014, The Cochrane database of systematic reviews.
[26] M. Silvestrini,et al. Seizure course during pregnancy in catamenial epilepsy , 2014, Neurology.
[27] Anup D. Patel,et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome , 2018, Neurology.
[28] D. Thurman,et al. How common are the “common” neurologic disorders? , 2007, Neurology.
[29] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[30] L. Degenhardt,et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[31] Anup D. Patel,et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial , 2016, The Lancet Neurology.
[32] M. Silvestrini,et al. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis , 2018, CNS Drugs.
[33] Anup D. Patel,et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome , 2018, The New England journal of medicine.
[34] P. Kwan,et al. Early identification of refractory epilepsy. , 2000, The New England journal of medicine.